Merck (MRK) says it sees Terns (TERN) deal hurting EPS by USD 0.17 in the first 12 months

Merck's announcement regarding the Terns deal indicating an EPS hit of USD 0.17 within the first year suggests a negative short-term outlook that could weigh on investor sentiment. This adjustment may prompt a reassessment of Merck's earnings trajectory and valuation by analysts, potentially impacting its share price and the broader pharmaceutical sector in conjunction. Keep an eye on how this affects market sentiment towards similar biotech deals and the overall stock.